Shore Capital Reiterates Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by Shore Capital in a report issued on Friday, MarketBeat reports.

AZN has been the topic of a number of other research reports. Citigroup restated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, May 28th. Jefferies Financial Group boosted their price target on shares of AstraZeneca from GBX 71 ($0.91) to GBX 74 ($0.95) and gave the company a “hold” rating in a research report on Tuesday, July 2nd. Barclays reissued an “overweight” rating and issued a £125 ($160.11) price target on shares of AstraZeneca in a report on Monday, April 8th. Berenberg Bank increased their target price on shares of AstraZeneca from £130 ($166.52) to £150 ($192.14) and gave the stock a “buy” rating in a report on Friday, June 7th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £110 ($140.90) target price on shares of AstraZeneca in a research note on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of £105.53 ($135.18).

AstraZeneca Stock Performance

Shares of AZN stock opened at £122.60 ($157.04) on Friday. The stock has a market capitalization of £190.03 billion, a PE ratio of 3,929.49, a price-to-earnings-growth ratio of 0.97 and a beta of 0.16. AstraZeneca has a 52-week low of GBX 9,461 ($121.19) and a 52-week high of £127.04 ($162.73). The stock’s 50-day moving average price is £122.84 and its 200 day moving average price is £111.94. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 92.51.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.